Expert Opinion on Emerging Drugs (EOED)

Expert Opinion on Emerging Drugs [ISSN 1472-8214]; [e-ISSN 1744-7623] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and editorial pieces on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Opinion on Emerging Drugs addresses the needs of pharmaceutical and academic scientists, research planners, pharmaceutical product managers, clinical opinion leaders and healthcare planners. Articles include the following key areas: Concise background to the subject matter Assessment of medical need for alternative or novel therapies Assessment of the market and anticipated changes over time Summary of current research goals Outline of the scientific rationale for the approach(es) considered Analysis of the competitive environment Discussion of potential development issues The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseases

Expert Opinion on Emerging Drugs (EOED) is :-

• International, Peer-Reviewed, Open Access, Refereed, the needs of pharmaceutical and academic scientists, research planners, pharmaceutical product managers, clinical opinion leaders, healthcare planners, Concise background to the subject matter, Summary of current research goals , Online or Print , Quarterly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1472-8214, E-ISSN: 1744-7623, Established: 1996, Impact Factor: 2.7
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE